Drug Trial Radar · NCT00162552
Clinical Trial of Pentoxifylline in Patient With Cirrhosis
Last checked: Nov 20, 2026Latest source record: Jan 17, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
342
Actual
Start
Aug 2004
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In patients with cirrhosis and liver failure, pro-inflammatory cytokines (TNF alpha) might be responsible of severe complications and death. Thus, the prevention of cytokine production should prevent complications and mortality. The aim of this study is to study the 2 months survival rate in patients with severe cirrhosis (Child-Pugh C) with pentoxifylline - an inhibitor of cytokine production. The 6 month mortality, the proportion of transplanted patients, the occurrence of complications (bacterial infection, renal failure, hepatic encephalopathy and gastrointestinal bleeding), plasma cytokine levels and fibrotest - a marker of fibrosis - will be also studied. This is a multicenter double blind randomized trial with a placebo. All adult patients with severe cirrhosis might be randomized after written consent. Patients with severe carcinoma, intolerance or contraindication to pentoxifylline will not be included. Patients receive either pentoxifylline or placebo 3 times a day for 6 months. Three hundred and forty two patients are necessary to decrease mortality rate by 50% at 2 months in a beta risk of 10% and an alpha risk of 5%. Patients will be seen every month.
Conditions
- Cirrhosis
- Liver Failure
Interventions
pentoxifyllineDrug
Patients with severe cirrhosis treated with Pentoxifylline
PLACEBODrug
Patients with severe cirrhosis treated with a placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- survival rate at 2 monthsTime frame: at 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Beaujon
Clichy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.